Your session is about to expire
← Back to Search
25 µg SpFN_1B-06-PL + ALFQ (QS21 Adjuvant) for COVID-19
Study Summary
This trial will test if a new COVID-19 vaccine is safe for adults, if it causes any side effects, and if it causes an immune response.
- COVID-19
Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Logistics
Participation is compensated
You will be compensated for participating in this trial.
Who is running the clinical trial?
Media Library
- You have other ongoing health problems or conditions.You have had a previous organ or stem cell transplant.You have a current or past problem with using drugs or alcohol that may prevent you from participating in the study, according to the doctor in charge.You have either type 1 or type 2 diabetes, including cases where you control it with diet alone. You also have a thyroid disease.
- Group 1: 1A: 25 µg of SpFN + ALFQ on Days 1, 29 and 181.
- Group 2: 1B: Placebo (Sodium chloride, USP, for injection (0.9% NaCl) on Days 1, 29 and 181.
- Group 3: 2A: 50 µg of SpFN + ALFQ on Days 1, 29, and 181.
- Group 4: 2B: Placebo (Sodium chloride, USP, for injection (0.9% NaCl) on Days 1, 29, and 181.
- Group 5: 3A: 50 µg of SpFN + ALFQ on Days 1 and 181.
- Group 6: 3B: Placebo (Sodium chloride, USP, for injection (0.9% NaCl) on Days 1 and 181.
- All Individual Drugs Already Approved - Therapies where all constituent drugs have already been approved are likely to have better-understood side effect profiles.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Have researchers conducted any past experiments with 25 µg SpFN_1B-06-PL + ALFQ (QS21 Adjuvant)?
"Presently, 100 medical studies are exploring the effects of 25 µg SpFN_1B-06-PL + ALFQ (QS21 Adjuvant), with a quarter of these trials in Phase 3. The hub for this research is Philadelphia, Pennsylvania but 385 other locations have been conducting their own experiments."
Has the combination of 25 µg SpFN_1B-06-PL and ALFQ (with QS21 Adjuvant) been sanctioned by the FDA?
"Given the limited data regarding efficacy and safety, our assessment concluded that 25 µg SpFN_1B-06-PL + ALFQ (QS21 Adjuvant) has a score of 1 on Power's scale from 1 to 3."
What is the current enrollment rate for this experiment?
"At the present moment, this particular research is not taking on any new participants. It was first posted to clinicaltrials.gov on April 5th 2021 and underwent its latest edit on September 13th 2021. If you're still interested in finding a suitable trial, 1045 studies related to Covid-19 are currently recruiting, as well as 100 trials for 25 µg SpFN_1B-06-PL + ALFQ (QS21 Adjuvant)."
Are there currently any available slots for participants in this clinical trial?
"Unfortunately, no new participants are being enrolled in this trial. It was first posted April 5th 2021 and last updated September 13th 2021. Other studies may be of interest; There are 1045 trials actively recruiting patients with Covid-19 and 100 trials enlisting volunteers for 25 µg SpFN_1B-06-PL + ALFQ (QS21 Adjuvant)."
Does this research endeavor permit the enrollment of individuals aged 55 or older?
"Based on the requirements of this trial, potential enrollees must be between 18 and 55 years old."
What primary indications are associated with 25 µg SpFN_1B-06-PL + ALFQ (QS21 Adjuvant)?
"25 µg SpFN_1B-06-PL + ALFQ (QS21 Adjuvant) can be employed to alleviate the symptoms of diarrhea. It is also useful for combating inflammation in the nasal mucosa, general surgical procedures, and corneal edema."
How can I become a participant in this investigative research?
"To qualify for this clinical trial, potential participants must have a covid-19 diagnosis and be between 18 to 55 years old. At present, the study is looking to enroll 29 patients in total."
Share this study with friends
Copy Link
Messenger